Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
We Optibiotix (OPTI) shareholders have been feeling a bit under the cosh of late as the shares weakened on a lack of news. It was just ennui among those of an impatient disposition but still it was annoying. This week's trading statement should reassure the doubters.
OptiBiotix says that it has made significant progress in its scientific programmes to develop compounds which modify the human microbiome to prevent, manage and treat disease. It lists a few but the one that grabs the attention is that it has demonstrated the ability of its novel oligosaccharides (carbohydrates that consist of a small number of sugars) to reduce cholesterol in human gut models by more than 20%. These sugars are heat resistant and stable during processing making them suitable as ingredients in a wide range of products.
What is of more note is a commercial update. The company states:
OptiBiotix reports that it has reached late stage commercial discussions with six commercial partners across its technology and product platforms. A number of these discussions have been ongoing for many months and have involved extensive due diligence of OptiBiotix's science, intellectual property, and the partners assessment of the scale of the market opportunity across international markets.
These discussions include a number of leading industry corporate players who provide product development, manufacturing, distribution, and/or routes to global markets.
Whilst OptiBiotix cannot guarantee that all discussions will lead to commercial deals it wants to update shareholders on the ongoing commercial progress being made across all of its products and platforms.
If just one big household name announces the revenue implications are such that shares will soar. But there are six chances for this. That is why we remain very excited. The shares are a touch ahead today at 64p-65.5p but are a BUY at up to 77p with a target to race past 100p when the big name commercial deals start landing.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments are turned off for this article.
Search ShareProphets |
Stock market news |
Recent Comments |